

HEALTHSOUTH[®]



Third Quarter 2012 Earnings Call

Supplemental Slides

Forward-Looking Statements

The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect our current outlook, views and plans with respect to future events, including legislative and regulatory developments, strategy, capital expenditures, development activities, dividend strategies, repurchase of securities, effective tax rates, financial performance, and business model. These estimates, projections and other forward-looking information are based on assumptions that HealthSouth believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material.

There can be no assurance that any estimates, projections or forward-looking information will be realized.

All such estimates, projections and forward-looking information speak only as of the date hereof.

HealthSouth undertakes no duty to publicly update or revise the information contained herein.

You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarters ended March 31, 2012, June 30, 2012, and September 30, 2012, when filed, and in other documents we previously filed with the SEC, many of which are beyond our control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein.

Note Regarding Presentation of Non-GAAP Financial Measures

The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. Our Form 8-K, dated October 25, 2012, to which the following supplemental slides are attached as Exhibit 99.2, provides further explanation and disclosure regarding our use of non-GAAP financial measures and should be read in conjunction with these supplemental slides.

Table of Contents

Q3 2012 Summary.....	4-8
Revenues (Q3 2012 vs. Q3 2011).....	9
Expenses (Q3 2012 vs. Q3 2011).....	10
Adjusted EBITDA.....	11
Earnings per Share.....	12
Adjusted Free Cash Flow	13-14
2012 Revised Guidance - Adjusted EBITDA	15
2012 Revised Guidance - EPS	16
Income Tax Considerations.....	17
Adjusted Free Cash Flow Considerations.....	18
Priorities for Reinvesting Free Cash Flows.....	19
Portfolio Growth.....	20-21
Appendix.....	22
Business Outlook: 2012 to 2014.....	23-25
Historic Discharge Growth vs. Industry.....	26
Debt Schedule.....	27
Revenues & Expenses (Sequential).....	28
Revenues & Expenses (9 Months).....	29
Payment Sources (Percent of Revenues)	30
Operational and Labor Metrics.....	31-32
Outstanding Share Summary and Warrant Information.....	33
Adjusted EBITDA History.....	34
Adjusted Free Cash Flow	35
Reconciliations to GAAP.....	36-41

Q3 2012 Summary (Q3 2012 vs. Q3 2011)



HealthSouth amended the joint venture agreement related to St. Vincent Rehabilitation Hospital which resulted in a change in accounting for this hospital from the equity method of accounting to a consolidated entity. The impact on HealthSouth's financials and operations can be found on slides 32 and 37.

✓ Revenue growth of 7.9%

- Inpatient revenue growth of 8.7%
 - Discharge growth of 4.2%
 - New-store growth was 2.5% (130 bps from St. Vincent consolidation)
 - Same-store discharge growth of 1.7%
 - Unfavorably impacted by a modest increase in length of stay in September (normalized in October)
 - Revenue per discharge increase of 4.4% (favorably impacted by length of stay)
- Outpatient and other revenue decline of 2.1% (\$0.8 million)

Q3 2012 Summary (Q3 2012 vs. Q3 2011)

✓ Improved operating leverage and labor productivity



✓ Adjusted EBITDA ⁽³⁾ for the quarter of \$125.2 million reflected growth of 13.3%.

✓ Adjusted free cash flow ⁽⁴⁾ for the quarter of \$71.6 million and \$186.8 million for first nine months of 2012 reflected:

- Continued adjusted EBITDA growth and lower interest expense
- The planned investment in the clinical information system and hospital refresh projects (see full-year assumptions on slide 18)
- The favorable impact on working capital for the quarter and first nine months due to the timing of an approx. \$12 million interest payment (see full-year assumptions on slide 18)

(1) General & Administrative excludes stock-based compensation.

(2) Hospital-related expenses include other operating expenses, supplies, and occupancy costs.

(3) Reconciliation to GAAP provided on slides 36, 38, 40, and 41.

(4) Reconciliation to GAAP provided on slide 35

Q3 2012 Summary (Q3 2012 vs. Q3 2011) (cont.)

- ✓ **Diluted earnings ⁽¹⁾ per share of \$0.44 reflected strong operating results (see table on slide 12).**
 - Q3 2012 diluted earnings per share of \$0.44 included two items having a net after tax impact of \$0.05 per share:
 - \$4.9 million gain on consolidation of St. Vincent Rehabilitation Hospital
 - \$3.5 million gain (recovery from Richard Scruschy) in government, class action, and related settlements
 - Q3 2011 diluted earnings per share of \$0.17 included a \$12.7 million, or \$0.08 per share after tax, loss on early extinguishment of debt.
 - Effective tax rate of approx. 37% in Q3 2012 compared to approx. 45% in Q3 2011

(1) Income from continuing operations attributable to HealthSouth

Q3 2012 Summary (cont.)

Growth:


- ✓ **Entered into a letter of intent to acquire Walton Rehabilitation Hospital, a 58-bed inpatient rehabilitation hospital owned by the Walton Rehabilitation Health System located in Augusta, GA.**
 - Expected to close in Q1 2013
- ✓ **Broke ground on a replacement hospital for HealthSouth Rehabilitation Hospital of Western Massachusetts (This hospital will be owned and will replace an existing leased facility.)**
- ✓ **Continued development and construction of hospitals in Ocala, FL, Stuart, FL, and Littleton, CO**

Capital structure and cash deployment:

- ✓ **Issued \$275 million of 5.75% Senior Notes maturing 2024**
 - Utilized a portion of the proceeds to pay down the \$195 million revolver balance
 - Initiated a call on 10% of the 2018 and 2022 Senior Notes; approx. \$65 million debt reduction recorded in Q4 2012

Q3 2012 Summary (cont.)

✓ HealthSouth Functional Outcomes Continue to Outpace Industry Average



FIM Gain

Change in Functional Independence Measurement (based on an 18 point assessment) from admission to discharge.

LOS Efficiency

Functional gain divided by length of stay.

* Average = Expected, Risk-adjusted

Source: UDSmr Database – On Demand Report: Q3 2012 Report

Revenues (Q3 2012 vs. Q3 2011)

<i>(Millions)</i>	Q3 2012	Q3 2011	Increase/ (Decrease)
Inpatient	\$ 498.9	\$ 458.8	8.7%
Outpatient and other	38.1	38.9	(2.1%)
Consolidated net operating	\$ 537.0	\$ 497.7	7.9%

(Actual Amounts)

Discharges	30,569	29,350	4.2%
Net patient revenue / discharge	\$ 16,320	\$ 15,632	4.4%

✓ Revenue growth of 7.9%

- Inpatient revenue growth of 8.7%
 - Discharge growth of 4.2%
 - New-store growth was 2.5% (130 bps from St. Vincent consolidation)
 - Same-store discharge growth of 1.7%
 - Unfavorably impacted by a modest increase in length of stay in September (normalized in October)
 - Revenue per discharge increase of 4.4% (favorably impacted by length of stay)
 - Price adjustments (Medicare and managed care)
 - Higher average acuity (CMI) for the patients we served
 - Higher percentage of Medicare patients
- Outpatient and other revenue declined by 2.1% (\$0.8 million)
 - Two fewer outpatient rehabilitation satellite clinics in Q3 2012

Expenses (Q3 2012 vs. Q3 2011)

<i>(Millions)</i>	Q3 2012	Q3 2011	Increase/ (Decrease)
Salaries and benefits	\$ 262.3	\$ 245.0	7.1%
Percent of net operating revenues	48.8%	49.2%	(40 bps)
EPOB (employees per occupied bed)	3.46	3.53	(2.0%)
Hospital-related expenses (other operating, supplies, occupancy)	\$ 111.0	\$ 107.5	3.3%
Percent of net operating revenues	20.7%	21.6%	(90 bps)
General and administrative (excludes stock-based compensation)	\$ 23.2	\$ 21.5	7.9%
Percent of net operating revenues	4.3%	4.3%	-
Provision for doubtful accounts	\$ 7.0	\$ 5.1	37.3%
Percent of net operating revenues	1.3%	1.0%	30 bps

- ✓ Continued improvement in operating leverage from 75.1% to 73.8% as a percent of revenue
 - Additional gains in labor productivity (EPOB) offset the higher cost of labor
 - Hospital-related expenses as a percent of revenue declined as a result of supply chain efficiencies and lower occupancy expense, offset by higher clinical information system implementation costs
- ✓ Anticipated increase in provision for doubtful accounts due to an increase in Medicare claims denials and a lengthening in the related adjudication process

Adjusted EBITDA ⁽¹⁾

(Millions)

	Q3		9 Months	
	2012	2011	2012	2011
Net operating revenues	\$ 537.0	\$ 497.7	\$ 1,609.0	\$ 1,508.8
Less: Provision for doubtful accounts	(7.0)	(5.1)	(19.8)	(14.9)
Net operating revenues less provision for doubtful accounts	530.0	492.6	1,589.2	1,493.9
Operating expenses:				
Salaries and benefits	(262.3)	(245.0)	(780.7)	(730.6)
Hospital-related expenses:				
Other operating expenses	(75.4)	(70.3)	(222.8)	(216.6)
Supplies	(23.8)	(24.7)	(76.2)	(76.7)
Occupancy costs	(11.8)	(12.5)	(36.6)	(36.2)
	(111.0)	(107.5)	(335.6)	(329.5)
General and administrative expenses ⁽²⁾	(23.2)	(21.5)	(69.2)	(66.3)
Equity in nonconsolidated affiliates	3.3	3.1	9.7	8.8
Other income ⁽³⁾	1.2	0.2	2.5	1.5
Noncontrolling interests ⁽⁴⁾	(12.8)	(11.4)	(38.6)	(34.5)
Adjusted EBITDA	\$ 125.2	\$ 110.5	\$ 377.3	\$ 343.3

(1) Reconciliation to GAAP provided on slides 36, 38, 40, and 41.

	Q3		9 Months	
	2012	2011	2012	2011
In arriving at Adjusted EBITDA, the following were excluded:				
(2) Stock-based compensation expense	6.1	4.9	18.1	14.4
(3) Gain on consolidation of St. Vincent Rehabilitation Hospital	4.9	-	4.9	-
(4) Noncontrolling interests related to discontinued operations	-	(0.1)	-	(1.1)

Adjusted EBITDA Change

Q3 2012	9 Months 2012
+\$14.7M	+\$34.0
+13.3%	+9.9%

Q3 2012 and 9 Months 2012 reflect:

- Revenue growth
- Improved operating leverage and labor productivity
- Higher labor cost
- Higher bad debt expense

Earnings per Share

(In Millions, Except Per Share Data)

	Q3		9 Months	
	2012	2011	2012	2011
Adjusted EBITDA	\$ 125.2	\$ 110.5	\$ 377.3	\$ 343.3
Interest expense and amortization of debt discounts and fees	(23.5)	(26.3)	(69.8)	(96.3)
Depreciation and amortization	(21.3)	(19.5)	(60.8)	(58.6)
Stock-based compensation expense	(6.1)	(4.9)	(18.1)	(14.4)
Non-cash loss on disposal of assets	(1.6)	(2.8)	(3.0)	(3.9)
	72.7	57.0	225.6	170.1
Certain nonrecurring expenses:				
Government, class action, and related settlements	3.5	-	3.5	10.6
Professional fees - accounting, tax, and legal	(4.1)	(4.0)	(13.2)	(16.2)
Loss on early extinguishment of debt	(1.3)	(12.7)	(1.3)	(38.8)
Gain on consolidation of St. Vincent Rehabilitation Hospital	4.9	-	4.9	-
Pre-tax income	75.7	40.3	219.5	125.7
Income tax expense ⁽¹⁾	(28.1)	(18.1)	(84.1)	(21.9) ⁽²⁾
Income from continuing operations ⁽³⁾	<u>\$ 47.6</u>	<u>\$ 22.2</u>	<u>\$ 135.4</u>	<u>\$ 103.8</u>
Basic shares	94.7	93.3	94.6	93.2
Diluted shares	108.1	109.2	108.2	109.1
Basic earnings per share ^{(3) (4)}	<u>\$ 0.44</u>	<u>\$ 0.17</u>	<u>\$ 1.23</u>	<u>\$ 0.90</u>
Diluted earnings per share ^{(3) (5)}	<u>\$ 0.44</u>	<u>\$ 0.17</u>	<u>\$ 1.23</u>	<u>\$ 0.90</u>

Earnings per Share from Continuing Operations ⁽³⁾

Q3 2012 and 9 Months 2012 reflect:

- Higher Adjusted EBITDA
- Lower interest expense
- Approx. 37% and 38% effective tax rate ⁽⁶⁾, respectively

Q3 2011 and 9 Months 2011 reflect:

- Higher nonrecurring expenses
- Approx. 45% and 17% effective tax rate ⁽⁶⁾, respectively

(1) Cash income tax expense was \$2.1 million, \$1.7 million, \$6.4 million, and \$5.9 million for Q3 2012 and 2011 and nine months 2012 and 2011, respectively.

(2) Includes a \$0.30 per share benefit related to the Company's settlement with the IRS for tax years 2007 and 2008 and a reduction in unrecognized tax benefits due to the lapse of the statute of limitations for certain federal and state claims

(3) Income from continuing operations attributable to HealthSouth

(4) The dividends related to our convertible perpetual preferred stock must be subtracted from income from continuing operations when calculating basic earnings per share.

(5) Diluted earnings per share on a GAAP basis are the same as basic earnings per share due to the antidilutive impact in Q3 2011 and nine months 2012 and 2011.

(6) Estimated effective tax rate using pre-tax income from continuing operations attributable to HealthSouth

Adjusted Free Cash Flow


<i>(Millions)</i>	Q3		9 Months	
	2012	2011	2012	2011
Net cash provided by operating activities	\$ 107.2	\$ 55.1	\$ 302.2	\$ 213.2
Impact of discontinued operations	0.2	(2.2)	(1.5)	(9.4)
Net cash provided by operating activities of continuing operations	107.4	52.9	300.7	203.8
Capital expenditures for maintenance	(17.9)	(12.8)	(68.0)	(35.1)
Net settlements on interest rate swaps	-	-	-	(10.9)
Dividends paid on convertible perpetual preferred stock	(5.8)	(6.5)	(18.9)	(19.5)
Distributions paid to noncontrolling interests of consolidated affiliates	(13.6)	(10.7)	(37.6)	(34.0)
Non-recurring items:				
Cash paid for professional fees - accounting, tax, and legal	4.1	4.0	13.2	16.2
Net premium on bond issuance/repayment	-	8.9	-	22.8
Cash paid for government, class action and related settlements	(2.6)	-	(2.6)	7.7
Income tax refunds related to prior periods	-	(3.5)	-	(6.9)
Adjusted free cash flow	\$ 71.6	\$ 32.3	\$ 186.8	\$ 144.1

✓ Adjusted free cash flow for Q3 2012 and 9 months 2012 reflected:

- Continued adjusted EBITDA growth and lower interest expense
- The planned investment in the clinical information system and hospital refresh projects (see full-year assumptions on slide 18)
- The favorable impact on working capital for the quarter and first nine months due to timing of an approx. \$12 million interest payment (see full-year assumptions on slide 18)

Adjusted Free Cash Flow (1)

(Millions)	9 Months		Change	
	2012	2011	\$	%
Adjusted free cash flow (1)	\$ 186.8	\$ 144.1	\$ 42.7	29.6%



(1) Reconciliation to GAAP provided on slide 35

(2) Reflects lower average borrowings and lower average interest rate

(3) Working capital was positively impacted during the period due to the timing of a \$12 million interest payment (see full-year assumptions on slide 18).

(4) Final swap payment was made in March 2011.

(5) Planned investment in clinical information system and hospital refresh projects

2012 Revised Guidance – Adjusted EBITDA⁽¹⁾

Original Guidance

Feb. 23, 2012

\$475 million to \$485 million

Revised Guidance

April 26, 2012

\$475 million to \$485 million;
(The high end of, or greater than)

July 26, 2012

\$487 million to \$495 million

Oct. 25, 2012

\$490 million to \$495 million

Includes approx. \$11 million employee bonus in lieu of October 1, 2012 merit increase

Q4 2012 Considerations:

- ✓ **Revenue growth of 3.6% to 5.2% (October through December 2012)**
 - Discharge growth between 2.5% and 3.5% (October through December 2012)
 - Revenue per discharge growth between 2.0% and 2.5% (October through December 2012)
 - The 2013 IRF-PPS final notice will result in a net increase of approx. 2.1% to our Medicare payment rate in Q4 2012.
- ✓ **Q4 2012 includes one-time bonus of approx. \$11 million in lieu of October 1, 2012 merit increase for all non-management employees (a 2.25% merit increase would have increased SWB by approx. \$5.5 million in Q4 2012).**
- ✓ **Installation of new clinical information system in twelve existing hospitals expected to increase operating expenses by approx. \$1 million in Q4 2012**
- ✓ **Higher workers' compensation expense of approx. \$2 million in Q4 2012**
- ✓ **Q4 2011 Adjusted EBITDA benefited by \$2.4 million from a nonrecurring franchise tax recovery**

⁽¹⁾ Reconciliation to GAAP provided on slides 36, 38, 40, and 41.

2012 Revised Guidance - EPS

Earnings per Share from
Continuing Operations
Attributable to HealthSouth ⁽¹⁾
\$1.49 to \$1.53

Based on results for the first 9 months of 2012, HealthSouth is raising its expectations for full-year 2012 results.

Considerations:

- ✓ Q4 2012 will include a \$2.7 million loss on early extinguishment of debt for the redemption of 10% of the 2018 and 2022 Senior Notes
- ✓ Assumes provision for income tax of approx. 39% in 2012 vs. approx. 19% in 2011 ⁽²⁾
- ✓ Cash taxes expected to be \$8 to \$12 million

	EPS Guidance		
	Actual	Low	High
	2011	2012	
<i>(In Millions, Except Per Share Data)</i>			
Adjusted EBITDA	\$ 466.2	\$ 490	\$ 495
Interest expense and amortization of debt discounts and fees	(119.4)	(95)	
Depreciation and amortization	(78.8)	(82)	
Stock-based compensation expense	(20.3)	(23)	
Other, including non-cash loss on disposal of assets	(4.3)	(7)	
	<u>243.4</u>	<u>283</u>	<u>288</u>
Certain Nonrecurring Expenses:			
Government, class action and related settlements	12.3	4	
Professional fees - accounting, tax and legal	(21.0)	(17)	
Loss on early extinguishment of debt	(38.8)	(4)	
Gain on consolidation of St. Vincent Rehabilitation Hospital	-	5	
Pre-tax income	195.9	271	276
Income tax (assumes 39% in 2012)	(37.1) ⁽³⁾	(105)	(107)
Income from continuing operations ⁽¹⁾	\$ 158.8	\$ 166	\$ 169
Basic shares	<u>93.3</u>	<u>94.6</u>	<u>94.6</u>
Earnings per share ⁽¹⁾⁽⁴⁾	\$ 1.42	\$ 1.49	\$ 1.53

(1) Income from continuing operations attributable to HealthSouth

(2) Estimated effective tax rate using pre-tax income from continuing operations attributable to HealthSouth

(3) Includes an approx. \$46 million, or \$0.49 per share, benefit primarily related to the Company's settlement with the IRS for tax years 2007 and 2008, a decrease in the valuation allowance, and a reduction in unrecognized tax benefits due to the lapse of the statute of limitations for certain federal and state claims

(4) The dividends related to our convertible perpetual preferred stock must be subtracted from income from continuing operations when calculating basic earnings per share.

Income Tax Considerations

GAAP Considerations:

- As of 9/30/12, the Company's federal NOL had a balance of approx. \$1.0 billion.
- The Company has a remaining valuation allowance of approx. \$49 million, primarily related to state NOLs.

Cash Tax Payments:

- The Company expects to pay approx. \$8 million to \$12 million per year of income tax.
- HealthSouth is not currently subject to an annual use limitation ("AUL") under Internal Revenue Code Section 382 ("Section 382"). A "change of ownership," as defined by Section 382, would subject the Company to an AUL, which is equal to the market capitalization of the Company at the time of the "change of ownership" multiplied by the long-term tax exempt rate.

Adjusted Free Cash Flow ⁽¹⁾ Considerations

- 2012 adjusted free cash flow growth reflects increased maintenance capital expenditures and working capital.
- Multi-year adjusted free cash flow CAGR of 12% to 17%

The increase in 2012 maintenance CAPEX is driven by the clinical information system roll-out, two major hospital renovations, and increased hospital refresh projects.

Certain Cash Flow Items ⁽²⁾ (millions)	2011 Actual	9 Months 2012 Actual	2012 Assumptions
▪ Cash interest expense ⁽³⁾	\$115.2	\$67.1	\$92
▪ Cash payments for taxes	\$9.1	\$9.6	\$8 to \$12
▪ Working capital and other	\$10.6	\$26.9	\$20 to \$30
▪ Maintenance CAPEX	\$50.8	\$68.0	\$75 to \$85
▪ Net cash swap-related settlements	\$10.9	-	-
▪ Dividends paid on preferred stock ⁽⁴⁾	\$26	\$18.9	\$24.6

(1) Reconciliation to GAAP provided on slide 35

(2) Definition of adjusted free cash flow is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, net settlements on interest rate swaps, dividends paid on preferred stock, distributions to noncontrolling interests, and nonrecurring items.

(3) Net of amortization of debt and discounts and fees

(4) Assumption for 2012 includes \$18.9 million for first nine months 2012 plus \$5.7 million funded on October 15, 2012.

Priorities for Reinvesting Free Cash Flows

		(millions)			
		2012 Assumptions	9 Months 2012	2011	
Priorities	Growth	Growth in core business			
		Bed expansions (80 - 100 beds)	\$20 to \$25	\$14.5	\$12.5
		De novo hospitals (complete Ocala; start 4 others)	\$50 to \$70	\$28.8	\$15.6
		Acquisitions (target 2/year) - Free standing IRFS - Hospital Unit	TBD	\$3.1	\$6.5
			\$70 to \$95, excluding acquisitions	\$46.4	\$34.6
Alternate Opportunities	Debt Reduction	Debt pay down, net		9 Months 2012	2011
		Purchase leased properties ⁽¹⁾		-	\$256.6
	Shareholder Distribution	Convertible preferred stock repurchase (\$125 million market repurchases)		\$9.4	\$28.6
		Common share repurchase (\$125 million authorization)		\$46.5	-
		Cash dividends (one time or regular)		-	-
			\$55.9	\$285.2	

(1) 2012 includes the purchase of the real estate (previously subject to an operating lease) associated with our joint venture hospital in Fayetteville, AR for approx. \$15 million, half of which was reimbursed to us by our joint venture partner through a capital contribution; also includes an initial investment for a replacement hospital for our currently leased hospital in Ludlow, MA.

Portfolio Growth: De Novo (40 bed) Assumptions and Timing

All projects have minimum IRR target of 15% (pre-tax).

Investment Considerations

- Target 4 openings/Year
- Cash Payback ⁽¹⁾ = 5 to 7 years
- Assumes sequestration in 2013
- Inclusive of CON costs (where applicable)
- Includes cost of CIS installation

- All private rooms
- A minimum of 30 patients treated for “zero” revenue (Medicare pre-certification)
- Core infrastructure of building anticipates future expansion; potential to enhance returns with future bed expansion

Capital Cost (millions)	Low	High	Operational Date	Location ⁽²⁾	Beds
Construction, design, permitting, etc.	\$11.5	\$15.5	TBD	Southwest Phoenix, AZ	40
Land	2.0	2.5	Q1 2014	Orlando, FL	50
Equipment (including CIS)	3.5	4.0	Q2 2013	Littleton, CO	40
	\$17.0	\$22.0	Q2 2013	Stuart, FL	34
Pre-Opening Expense (thousands)	Low	High	Q4 2012	Ocala, FL	40
Operating	\$200	\$300	Q4 2011	Cypress, TX	40
Salaries, wages, benefits	150	200	Q3 2010	Bristol, VA	25
			Q2 2010	Loudoun County, VA	40
	\$350	\$500	Q3 2009	Mesa, AZ	40

(1) Future cash payback periods may increase when the Company exhausts its significant NOLs (slide 17).

(2) Does not include Middletown, DE or Williamson Co., TN where CON awards are under appeal

Portfolio Growth: Acquisition Assumptions, Timing and Performance

All projects have minimum IRR target of 15% (pre-tax).

Acquisition Assumptions

Investment Considerations

- Cash Payback ⁽¹⁾ = 4 to 6 years
- Target: 2 acquisitions/Year
- Assumes sequestration in 2013

Value Added

- TeamWorks approach to sales/marketing
- Labor management tools and “best practices”
- Clinical expertise
- Clinical technology and programming
- Supply chain efficiency
- Medical leadership and clinical advisory boards

Unit Acquisitions

Location	Beds	Date Acquired
San Antonio, TX	34	Q3 2012
Ft. Smith, AR	30	Q3 2010
Little Rock, AR	23	Q1 2010
Altoona, PA	18	Q4 2009
Arlington, TX	30	Q3 2008

IRF Acquisition

Location	Date Acquired	Acquired Census	One year Later Census
Augusta, GA	TBD	TBD	TBD
Cincinnati, OH	Q4 2011	0	9 months census = 28
Sugar Land, TX	Q3 2010	26	35
Las Vegas, NV	Q2 2010	16	35
Vineland, NJ	Q3 2008	26	31

(1) Future cash payback periods may increase when the Company exhausts its significant NOLs (slide 17).

Appendix

Business Outlook: 2012 to 2014

Business Model

- Adjusted EBITDA CAGR: 5-8% ⁽¹⁾⁽²⁾
- Adjusted Free Cash Flow CAGR: 12-17% ⁽¹⁾⁽²⁾

Strategy	2011	2012	2013	2014
Delevering ⁽³⁾	Achieved < 3.0x Debt to Adj. EBITDA	< 3.0x Debt to Adj. EBITDA (subject to operating environment)		
Core Growth	Same-store Growth (Includes bed expansions and unit consolidations)			
	De novos 1- Cypress, TX	De novos 1- Ocala, FL	De novos (target of 4/year)	
	IRF Acquisitions 1- Drake, OH	IRF Acquisitions (target of 2/year)		
Opportunistic Growth				<p>Consider opportunistic, disciplined acquisitions of complementary post-acute services</p> <p>Key Considerations:</p> <ul style="list-style-type: none"> • Regulatory clarity • Market conditions • Purchase price and terms and conditions
Key Operational Initiatives	<ul style="list-style-type: none"> • Clinical Information System (CIS) Pilot 	<ul style="list-style-type: none"> • CIS Company-wide Implementation 		
	<ul style="list-style-type: none"> • Beacon (Management Reporting Software) = Labor / outcomes / quality optimization • TeamWorks = Care Management • "CPR" (Comfort, Professionalism, Respect) Initiative 			

(1) Reconciliation to GAAP provided on slides 35, 36, 38, 40, and 41.

(2) These are multi-year CAGRs; annual results may fall outside the range.

(3) Exclusive of any E&Y recovery.


Business Outlook: Revenue Assumptions

Revenue

Volume

- 2.5% to 3.5% annual growth (excludes acquisitions)
- Includes bed expansions, de novos and unit consolidations

Pricing



Medicare Pricing

	FY 2012 Q4 11 - Q3 12	FY 2013 ⁽³⁾ Q4 12 - Q3 13	FY 2014 Q4 13 - Q3 14
Market basket update ⁽¹⁾	2.9%	2.7%	2.9%
Healthcare reform reduction	10 bps	10 bps	30 bps
Productivity adjustment ⁽¹⁾	100 bps	70 bps	~ 110 bps

Managed Care Expected Price Increases

2012	2013	2014
3-5%	2-4%	2-4%

2% Sequestration ⁽²⁾

- (1) Medicare IRF-PPS Rule for 2012, Medicare IRF-PPS Notice for FY 2013, and management's estimates for FY 2014.
- (2) The Budget Control Act of 2011 includes a reduction of up to 2% to Medicare payments for all providers upon executive order of the President in January 2013. The reduction would be made from whatever level of payment would otherwise be provided under Medicare law and regulation. We currently estimate this automatic reduction, known as "sequestration," will result in a net decrease to our net operating revenues of approx. \$34 million annually in 2013.
- (3) We believe based on the Medicare IRF-PPS Notice for FY 2013, HealthSouth should realize a net increase of approx. 2.1% in FY 2013 before applying the effect of sequestration.

Business Outlook: Expense Assumptions

Expense

Salaries & Benefits ⁽¹⁾

	2012	2013	2014
Merit increases ⁽²⁾	~2%	0.5-0.6%	2.25-2.5%
Benefit costs increases	5-8%	8-10% ⁽²⁾	5-8%

Hospital Expenses

- Other operating expenses and supply costs tracking with inflation
- Occupancy costs relatively constant as percent of revenue
- Bad debt expense of approx. 1.3% to 1.5%

Merit increase assumptions will be updated in early 2013 when we roll the three year "Business Outlook" forward.



General and Administrative

~4.5% of revenue
(excludes stock-based compensation)

(1) Salaries, Wages and Benefits: ~ 90% Salaries and Wages; ~10% Benefits.

(2) Q1 2012 thru Q3 2012 includes an approx. 2% merit increase for non-management employees. In Q4 2012, the Company will pay an approx. \$11 million employee bonus in lieu of an October 1, 2012 merit increase for non-management employees. The 0.5-0.6% represents a 2.25-2.5% increase effective October 1, 2013. Because the October 1, 2012 merit increases were foregone, the Company expects to absorb all of the benefit costs increases in 2013.

Historic Discharge Growth vs. Industry


HealthSouth's volume growth has outpaced competitors'

Same Store HealthSouth vs. Industry



Q111 vs. Q110 Q211 vs. Q210 Q311 vs. Q310 Q411 vs. Q410 | Q112 vs. Q111 Q212 vs. Q211 Q312 vs. Q311

Quarterly Discharge Growth



Yearly Discharge Growth	2008	2009	2010	2011	2012 (9 Months)
	6.9%	5.6%	3.1%	5.2%	4.4%

- TeamWorks = standardized and enhanced sales & marketing
- Bed additions will help facilitate continued organic growth

(1) Data provided by UDSMR, a data gathering and analysis organization for the rehabilitation industry; represents ~ 65-70% of industry, including HealthSouth sites.

(2) Includes consolidated HealthSouth inpatient rehabilitation hospitals classified as same store during that time period.

Debt Schedule

(Millions)	Corporate	Credit Rating		Pro Forma Post Redemption ⁽¹⁾	Sept. 30, 2012	Dec. 31, 2011	Change in Debt vs. YE 2011
		S&P BB-	Moody Ba3				
Advances under \$600 million revolving credit facility, August 2017 - 3 Month LIBOR +175bps							
		BB+	Baa3	\$ -	\$ -	\$ -	\$ -
Advances under \$500 million revolving credit facility, May 2016 - 3 Month LIBOR +225bps							
		BB+	Baa3	-	-	110.0	(110.0)
Term loan facility, May 2016 - 3 Month LIBOR +225bps							
		BB+	Baa3	-	-	97.5	(97.5)
Bonds Payable:							
	7.25% Senior Notes due 2018 ⁽¹⁾	BB-	B1	302.9	336.6	336.7	(0.1)
	8.125% Senior Notes due 2020	BB-	B1	286.1	286.1	285.8	0.3
	7.75% Senior Notes due 2022 ⁽¹⁾	BB-	B1	280.7	311.9	312.0	(0.1)
	5.75% Senior Notes due 2024	BB-	B1	275.0	275.0	-	275.0
	Other bonds payable			-	-	1.5	(1.5)
	Other notes payable			37.3	37.3	35.3	2.0
	Capital lease obligations			75.0	75.0	75.9	(0.9)
	Long-term debt			\$ 1,257.0	\$ 1,321.9	\$ 1,254.7	\$ 67.2
	Debt to Adjusted EBITDA ⁽²⁾			2.5x	2.6x	2.7x	

(1) Redeemed 10% of the 2018 and 2022 notes on October 9, 2012

(2) Based on 4 Qtr trailing and 2011 Adjusted EBITDA of \$500.2 million, \$500.2 million, and \$466.2 million, respectively; reconciliation to GAAP provided on slides 36, 38, 40, and 41.

Revenues & Expenses (Sequential)

	Q3 2012	Q2 2012	Increase/ (Decrease)
Revenues (millions)			
Inpatient	\$ 498.9	\$ 495.0	0.8%
Outpatient and other	38.1	38.4	(0.8%)
Consolidated net operating	<u>\$ 537.0</u>	<u>\$ 533.4</u>	<u>0.7%</u>
(Actual Amounts)			
Discharges	30,569	30,719	(0.5%)
Net patient revenue / discharge	\$ 16,320	\$ 16,114	1.3%
Expenses (millions)			
Salaries and benefits	\$ 262.3	\$ 257.4	1.9%
Percent of net operating revenues	48.8%	48.3%	50 bps
EPOB (employees per occupied bed)	3.46	3.41	1.5%
Hospital-related expenses	\$ 111.0	\$ 112.6	(1.4%)
(other operating, supplies, occupancy, bad debts)			
Percent of net operating revenues	20.7%	21.1%	(40 bps)
General and administrative	\$ 23.2	\$ 22.1	5.0%
(excludes stock-based compensation)			
Percent of net operating revenues	4.3%	4.1%	20 bps
Provision for doubtful accounts	\$ 7.0	\$ 6.5	7.7%
Percent of net operating revenues	1.3%	1.2%	10 bps

Revenues & Expenses (9 months)

Revenues (millions)	9 Months 2012	9 Months 2011	Increase/ (Decrease)
Inpatient	\$ 1,494.5	\$ 1,386.3	7.8%
Outpatient and other	114.5	122.5	(6.5%)
Consolidated net operating	<u>\$ 1,609.0</u>	<u>\$ 1,508.8</u>	<u>6.6%</u>
(Actual Amounts)			
Discharges	92,159	88,288	4.4%
Net patient revenue / discharge	\$ 16,217	\$ 15,702	3.3%
Expenses (millions)			
Salaries and benefits	\$ 780.7	\$ 730.6	6.9%
Percent of net operating revenues	48.5%	48.4%	10 bps
EPOB (employees per occupied bed)	3.41	3.47	(1.7%)
Hospital-related expenses	\$ 335.6	\$ 329.5	1.9%
(other operating, supplies, occupancy, bad debts)			
Percent of net operating revenues	20.9%	21.8%	(90 bps)
General and administrative	\$ 69.2	\$ 66.3	4.4%
(excludes stock-based compensation)			
Percent of net operating revenues	4.3%	4.4%	(10 bps)
Provision for doubtful accounts	\$ 19.8	\$ 14.9	32.9%
Percent of net operating revenues	1.2%	1.0%	20 bps

Payment Sources (Percent of Revenues)

	Q3		9 Months		Full Year
	2012	2011	2012	2011	2011
Medicare	73.1%	72.0%	73.1%	71.8%	72.0%
Medicaid	1.4%	1.6%	1.3%	1.7%	1.6%
Workers' compensation	1.5%	1.6%	1.5%	1.7%	1.6%
Managed care and other discount plans ⁽¹⁾	19.1%	20.0%	19.4%	19.8%	19.8%
Other third-party payors	2.0%	1.9%	1.8%	2.0%	2.0%
Patients	1.4%	1.3%	1.4%	1.2%	1.2%
Other income	1.5%	1.6%	1.5%	1.8%	1.8%
Total	100.0%	100.0%	100.0%	100.0%	100.0%

(1) Managed Medicare revenues represent ~ 7%, 8%, 7%, 7%, and 7% of total revenues for Q3 2012, Q3 2011, 9 months 2012 and 2011, and full-year 2011, respectively, and are included in "Managed care and other discount plans."

Operational and Labor Metrics

	Q3 2012	Q2 2012	Q1 2012	Q4 2011	Q3 2011	Q2 2011	Q1 2011	9 Months 2012	9 Months 2011	Full Year 2011
--	------------	------------	------------	------------	------------	------------	------------	------------------	------------------	-------------------

(In Millions)

Net patient revenue-inpatient	\$ 498.9	\$ 495.0	\$ 500.6	\$ 480.1	\$ 458.8	\$ 465.4	\$ 462.1	\$ 1,494.5	\$ 1,386.3	\$ 1,866.4
Net patient revenue-outpatient and other revenues	38.1	38.4	38.0	38.0	38.9	39.7	43.9	114.5	122.5	160.5
Net operating revenues	<u>\$ 537.0</u>	<u>\$ 533.4</u>	<u>\$ 538.6</u>	<u>\$ 518.1</u>	<u>\$ 497.7</u>	<u>\$ 505.1</u>	<u>\$ 506.0</u>	<u>\$ 1,609.0</u>	<u>\$ 1,508.8</u>	<u>\$ 2,026.9</u>

(Actual Amounts)

Discharges ⁽¹⁾	30,569	30,719	30,871	30,066	29,350	29,811	29,127	92,159	88,288	118,354
Outpatient visits	221,648	229,152	231,243	225,062	236,969	244,647	236,761	682,043	718,377	943,439
Average length of stay	13.6	13.4	13.5	13.4	13.4	13.4	13.8	13.5	13.5	13.5
Occupancy %	68.3%	69.2%	70.7%	67.7%	67.2%	69.0%	70.2%	68.8%	68.6%	67.7%
# of licensed beds	6,598	6,538	6,500	6,461	6,376	6,356	6,350	6,598	6,376	6,461
Occupied beds	4,506	4,524	4,596	4,374	4,285	4,386	4,458	4,539	4,374	4,374

Full-time equivalents (FTEs) ⁽²⁾	15,545	15,378	15,271	15,079	15,081	15,150	15,045	15,398	15,092	15,089
Contract labor	61	56	69	56	60	76	89	62	75	70
Total FTE and contract labor	<u>15,606</u>	<u>15,434</u>	<u>15,340</u>	<u>15,135</u>	<u>15,141</u>	<u>15,226</u>	<u>15,134</u>	<u>15,460</u>	<u>15,167</u>	<u>15,159</u>

EPOB ⁽³⁾	3.46	3.41	3.34	3.46	3.53	3.47	3.39	3.41	3.47	3.47
---------------------	------	------	------	------	------	------	------	------	------	------

- (1) Represents discharges from HealthSouth's 97 consolidated hospitals in Q3 2012; 96 consolidated hospitals in Q2 2012, Q1 2012, and Q4 2011; 94 consolidated hospitals in Q3 2011, Q2 2011, and Q1 2011.
- (2) Excludes approximately 400 full-time equivalents who are considered part of corporate overhead with their salaries and benefits included in general and administrative expenses in the Company's consolidated statements of operations. Full-time equivalents included in the above table represent HealthSouth employees who participate in or support the operations of the Company's hospitals.
- (3) Employees per occupied bed, or "EPOB," is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company's occupancy percentage.

Operational and Labor Metrics – Impact of St. Vincent Rehabilitation Hospital Consolidation

	St. Vincent Rehabilitation Hospital as Consolidated Entity	St. Vincent Rehabilitation Hospital as Equity Method Entity	
	Q3 2012 As Reported	Q3 2012 Without Accounting Change (In Millions)	Difference
Net patient revenue-inpatient	\$ 498.9	\$ 493.2	\$ 5.7
Net patient revenue-outpatient and other revenues	38.1	38.0	0.1
Net operating revenues	<u>\$ 537.0</u>	<u>\$ 531.2</u>	<u>\$ 5.8</u>

Actual Amounts

Discharges ⁽¹⁾	30,569	30,199	370
Outpatient visits	221,648	219,566	2,082
Average length of stay (days)	13.6	13.6	-
Occupancy %	68.3%	68.1%	0.2%
# of licensed beds	6,598	6,538	60
Occupied beds	4,506	4,452	54
Full-time equivalents (FTEs) ⁽¹⁾	15,545	15,388	157
Contract labor	61	59	2
Total FTE and contract labor	<u>15,606</u>	<u>15,447</u>	<u>159</u>

EPOB ⁽¹⁾	3.46	3.47	(0.01)
---------------------	------	------	--------

(1) See footnotes on slide 31.

Outstanding Share Summary and Warrant Information

(Millions)

	Weighted Average for the Period					
	Q3	Q3	9 Months	9 Months	FY	FY
	2012	2011	2012	2011	2011	2010
Basic shares outstanding ^{(1) (2)}	94.7	93.3	94.6	93.2	93.3	92.8
Diluted shares outstanding ^{(1) (2) (3)}	108.1	109.2	108.2	109.1	109.2	108.5

	End of Period					
	Q3	Q3	9 Months	9 Months	FY	FY
	2012	2011	2012	2011	2011	2010
Basic shares outstanding ^{(1) (2)}	94.6	93.3	94.6	93.3	93.3	92.8
Convertible perpetual preferred stock	0.353	0.400	0.353	0.400	0.400	0.400
If converted, equivalent common shares	11.6	13.1	11.6	13.1	13.1	13.1

Notes:

- (1) Does not include 2.0 million warrants issued in connection with a January 2004 loan repaid to Credit Suisse First Boston. In connection with this transaction, we issued warrants to the lender to purchase two million shares of our common stock. Each warrant has a term of ten years from the date of issuance (expire January 16, 2014) and an exercise price of \$32.50 per share. The warrants were not assumed exercised for dilutive shares outstanding because they were antidilutive in the periods presented.
- (2) The agreement to settle our class action securities litigation received final court approval in January 2007. These shares of common stock and warrants were issued on September 30, 2009. The 5.0 million of common shares are now included in the outstanding shares. The warrants to purchase approx. 8.2 million shares of common stock at a strike price of \$41.40 (expire January 17, 2017) were not assumed exercised for the dilutive shares outstanding because they were antidilutive in the periods presented.
- (3) The difference between the basic and diluted shares outstanding is primarily related to our convertible perpetual preferred stock (convertible into 11.6 million common shares at the end of Q3 2012). The preferred stock is convertible, at the option of the holder, at any time into shares of common stock at an initial conversion price of \$30.50 per share, which is equal to an initial conversion rate of approximately 32.7869 shares of common stock per share of preferred stock, subject to a specified adjustment. We may at any time cause the shares of preferred stock to be automatically converted into shares of our common stock at the conversion rate then in effect if the closing price of our common stock for 20 trading days within a period of 30 consecutive trading days ending on the trading day before the date we give the notice of forced conversion exceeds 150% of the conversion price of the preferred stock. In the first 9 months of 2012, the Company repurchased 46,645 shares of its convertible perpetual preferred stock.

Adjusted EBITDA ⁽¹⁾ History

(Millions)	Q3 2012	Q2 2012	Q1 2012	Q4 2011	Q3 2011	Q2 2011	Q1 2011	9 Months 2012	9 Months 2011	Full Year 2011
Net operating revenues	\$ 537.0	\$ 533.4	\$ 538.6	\$ 518.1	\$ 497.7	\$ 505.1	\$ 506.0	\$ 1,609.0	\$ 1,508.8	\$ 2,026.9
Less: Provision for doubtful accounts	(7.0)	(6.5)	(6.3)	(6.1)	(5.1)	(5.0)	(4.8)	(19.8)	(14.9)	(21.0)
Net operating revenues less provision for doubtful accounts	530.0	526.9	532.3	512.0	492.6	500.1	501.2	1,589.2	1,493.9	2,005.9
Operating expenses:										
Salaries and benefits	(262.3)	(257.4)	(261.0)	(251.4)	(245.0)	(241.6)	(244.0)	(780.7)	(730.6)	(982.0)
Hospital-related expenses:										
Other operating expenses	(75.4)	(74.4)	(73.0)	(67.4)	(70.3)	(75.4)	(70.9)	(222.8)	(216.6)	(284.0)
Supplies	(23.8)	(25.9)	(26.5)	(26.1)	(24.7)	(26.2)	(25.8)	(76.2)	(76.7)	(102.8)
Occupancy costs	(11.8)	(12.3)	(12.5)	(12.2)	(12.5)	(12.1)	(11.6)	(36.6)	(36.2)	(48.4)
	(111.0)	(112.6)	(112.0)	(105.7)	(107.5)	(113.7)	(108.3)	(335.6)	(329.5)	(435.2)
General and administrative expenses ⁽²⁾	(23.2)	(22.1)	(23.9)	(23.9)	(21.5)	(22.1)	(22.7)	(69.2)	(66.3)	(90.2)
Equity in nonconsolidated affiliates	3.3	3.1	3.3	3.2	3.1	3.2	2.5	9.7	8.8	12.0
Other income ⁽³⁾	1.2	0.4	0.9	1.2	0.2	0.7	0.6	2.5	1.5	2.7
Noncontrolling interests ⁽⁴⁾	(12.8)	(13.2)	(12.6)	(12.5)	(11.4)	(11.3)	(11.8)	(38.6)	(34.5)	(47.0)
Adjusted EBITDA	\$ 125.2	\$ 125.1	\$ 127.0	\$ 122.9	\$ 110.5	\$ 115.3	\$ 117.5	\$ 377.3	\$ 343.3	\$ 466.2

(1) Reconciliation to GAAP provided on slides 36, 38, 40, and 41.

	Q3 2012	Q2 2012	Q1 2012	Q4 2011	Q3 2011	Q2 2011	Q1 2011	9 Months 2012	9 Month 2011	Full Year 2011
In arriving at Adjusted EBITDA, the following were excluded:										
(2) Stock-based compensation expense	\$ 6.1	\$ 5.9	\$ 6.1	\$ 5.9	\$ 4.9	\$ 5.3	\$ 4.2	\$ 18.1	\$ 14.4	\$ 20.3
(3) Gain on consolidation of St. Vincent Rehabilitation Hospital	4.9	-	-	-	-	-	-	4.9	-	-
(4) Noncontrolling interests related to discontinued operations	-	-	-	-	(0.1)	(0.9)	(0.1)	-	(1.1)	(1.1)

Adjusted Free Cash Flow

(Millions)	Q3		9 Months		Full Year				
	2012	2011	2012	2011	2011	2010	2009	2008	2007
Net cash provided by operating activities	\$ 107.2	\$ 55.1	\$ 302.2	\$ 213.2	\$ 342.7	\$ 331.0	\$ 406.1	\$ 227.2	\$ 230.6
Impact of discontinued operations	0.2	(2.2)	(1.5)	(9.4)	(9.1)	(13.2)	(5.7)	(32.5)	(3.3)
Net cash provided by operating activities of continuing operations	107.4	52.9	300.7	203.8	333.6	317.8	400.4	194.7	227.3
Capital expenditures for maintenance ⁽¹⁾	(17.9)	(12.8)	(68.0)	(35.1)	(50.8)	(37.9)	(33.2)	(41.5)	(22.4)
Net settlements on interest rate swaps ⁽²⁾	-	-	-	(10.9)	(10.9)	(44.7)	(42.2)	(20.7)	0.1
Dividends paid on convertible perpetual preferred stock	(5.8)	(6.5)	(18.9)	(19.5)	(26.0)	(26.0)	(26.0)	(26.0)	(26.0)
Distributions paid to noncontrolling interests of consolidated affiliates	(13.6)	(10.7)	(37.6)	(34.0)	(44.2)	(34.4)	(32.6)	(33.4)	(23.4)
Non-recurring items:									
UBS Settlement proceeds, less fees to derivative plaintiffs' attorneys	-	-	-	-	-	-	(73.8)	-	-
Net premium paid (received) on bond issuance/redemption	-	8.9	-	22.8	22.8	-	-	-	-
Cash paid for professional fees - accounting, tax and legal	4.1	4.0	13.2	16.2	21.0	17.2	15.3	18.2	51.6
Cash paid for government, class action and related settlements	(2.6)	-	(2.6)	7.7	5.7	2.9	11.2	7.4	171.4
Income tax refunds related to prior periods	-	(3.5)	-	(6.9)	(7.9)	(13.5)	(63.7)	(89.4)	(457.7)
Adjusted free cash flow	\$ 71.6	\$ 32.3	\$ 186.8	\$ 144.1	\$ 243.3	\$ 181.4	\$ 155.4	\$ 9.3	\$ (79.1)

(1) Maintenance capital expenditures are expected to be \$75 to \$85 million in 2012.

(2) Final swap payment of \$10.9 million was made in March 2011.

Reconciliation of Net Income to Adjusted EBITDA ⁽¹⁾

(in millions, except per share data)	2012							
	Q1		Q2		Q3		9 Months	
	Total	Per Share						
Net income	\$ 56.8		\$ 59.9		\$ 59.9		\$ 176.6	
Loss (income) from disc ops, net of tax, attributable to HealthSouth	0.4		(3.5)		0.5		(2.6)	
Net income attributable to noncontrolling interests	(12.6)		(13.2)		(12.8)		(38.6)	
Income from continuing operations attributable to HealthSouth ⁽²⁾	44.6	\$ 0.40	43.2	\$ 0.39	47.6	\$ 0.44	135.4	\$ 1.23
Gov't, class action, and related settlements	-		-		(3.5)		(3.5)	
Pro fees - acct, tax, and legal	3.6		5.5		4.1		13.2	
Provision for income tax expense	29.1		26.9		28.1		84.1	
Interest expense and amortization of debt discounts and fees	23.3		23.0		23.5		69.8	
Depreciation and amortization	19.5		20.0		21.3		60.8	
Loss on early extinguishment of debt	-		-		1.3		1.3	
Gain on consolidation of St. Vincent Rehabilitation Hospital	-		-		(4.9)		(4.9)	
Net noncash loss on disposal of assets	0.8		0.6		1.6		3.0	
Stock-based compensation expense	6.1		5.9		6.1		18.1	
Adjusted EBITDA ⁽¹⁾	<u>\$ 127.0</u>		<u>\$ 125.1</u>		<u>\$ 125.2</u>		<u>\$ 377.3</u>	
Weighted average common shares outstanding:								
Basic		<u>94.5</u>		<u>94.6</u>		<u>94.7</u>		<u>94.6</u>
Diluted		<u>108.7</u>		<u>108.0</u>		<u>108.1</u>		<u>108.2</u>

(1) (2) – Notes on page 40.

Reconciliation of Net Income to Adjusted EBITDA ⁽¹⁾ - Impact of Consolidation of St. Vincent Rehabilitation Hospital

	St. Vincent Rehabilitation Hospital as Consolidated Entity		St. Vincent Rehabilitation Hospital as Equity Method Entity		Difference	
	Q3 2012 As Reported		Q3 2012 Without Accounting Change			
	Total	Per Share	Total	Per Share	Total	Per Share
Net income	\$ 59.9		\$ 56.4		\$ 3.5	
Loss (income) from discops, net of tax, attributable to HealthSouth	0.5		0.5		-	
Net income attributable to noncontrolling interests	(12.8)		(12.2)		(0.6)	
Income from continuing operations attributable to HealthSouth ⁽²⁾	47.6	<u>\$ 0.44</u>	44.7	<u>\$ 0.41</u>	2.9	<u>\$ 0.03</u>
Gov't, class action, and related settlements	(3.5)		(3.5)		-	
Pro fees—acct, tax, and legal	4.1		4.1		-	
Provision for income tax expense	28.1		26.2		1.9	
Interest expense and amortization of debt discounts and fees	23.5		23.3		0.2	
Depreciation and amortization	21.3		20.9		0.4	
Loss on early extinguishment of debt	1.3		1.3		-	
Gain on consolidation of St. Vincent Rehabilitation Hospital	(4.9)		-		(4.9)	
Net noncash loss on disposal of assets	1.6		1.6		-	
Stock-based compensation expense	6.1		6.1		-	
Adjusted EBITDA	<u>\$ 125.2</u>		<u>\$ 124.7</u>		<u>\$ 0.5</u>	
Weighted average common shares outstanding:						
Basic		<u>94.7</u>		<u>94.7</u>		-
Diluted		<u>108.1</u>		<u>108.1</u>		-

(1) (2) – Notes on page 40.

Reconciliation of Net Income to Adjusted EBITDA ⁽¹⁾

(in millions, except per share data)	2011									
	Q1		Q2		Q3		Q4		Full Year	
	Total	Per Share	Total	Per Share						
Net income	\$ 91.5		\$ 32.3		\$ 68.3		\$ 62.5		\$ 254.6	
(Income) loss from disc ops, net of tax, attributable to HealthSouth	(17.6)		(2.5)		(34.8)		5.0		(49.9)	
Net income attributable to noncontrolling interests	(11.7)		(10.4)		(11.3)		(12.5)		(45.9)	
Income from continuing operations attributable to HealthSouth ⁽²⁾	62.2	\$ 0.57	19.4	\$ 0.14	22.2	\$ 0.17	55.0	\$ 0.50	158.8	\$ 1.42
Gov't, class action, and related settlements	-		(10.6)		-		(1.7)		(12.3)	
Pro fees - acct, tax, and legal	3.8		8.4		4.0		4.8		21.0	
Provision for income tax (benefit) expense	(7.4)		11.2		18.1		15.2		37.1	
Interest expense and amortization of debt discounts and fees	35.1		34.9		26.3		23.1		119.4	
Depreciation and amortization	19.5		19.6		19.5		20.2		78.8	
Loss on early extinguishment of debt	-		26.1		12.7		-		38.8	
Net noncash loss on disposal of assets	0.1		1.0		2.8		0.4		4.3	
Stock-based compensation expense	4.2		5.3		4.9		5.9		20.3	
Adjusted EBITDA ⁽¹⁾	\$ 117.5		\$ 115.3		\$ 110.5		\$ 122.9		\$ 466.2	
Weighted average common shares outstanding:										
Basic		93.1		93.3		93.3		93.3		93.3
Diluted		109.0		109.5		109.2		109.1		109.2

(1) (2) – Notes on page 40.

Reconciliation of Net Income to Adjusted EBITDA ⁽¹⁾

(in millions, except per share data)	Full Year							
	2007		2008		2009		2010	
	Total	Per Share	Total	Per Share	Total	Per Share	Total	Per Share
Net income	\$ 718.7		\$ 281.8		\$ 128.8		\$ 939.8	
Income from disc ops, net of tax, attributable to HealthSouth	(462.4)		(32.5)		(17.7)		(9.2)	
Net income attributable to noncontrolling interests	(65.3)		(29.4)		(34.0)		(40.8)	
Income from continuing operations attributable to HealthSouth ⁽²⁾	191.0	\$ 2.08	219.9	\$ 2.28	77.1	\$ 0.58	889.8	\$ 8.20
Gain on UBS Settlement	-		(121.3)		-		-	
Gov't, class action, and related settlements	(2.8)		(67.2)		36.7		1.1	
Pro fees - acct, tax, and legal	51.6		44.4		8.8		17.2	
Loss on interest rate swaps	30.4		55.7		19.6		13.3	
Provision for income tax benefit	(325.6)		(69.1)		(2.9)		(740.8)	
Interest expense and amortization of debt discounts and fees	229.2		159.3		125.7		125.6	
Depreciation and amortization	71.3		78.9		67.6		73.1	
Impairment charges, including investments	15.1		2.4		1.4		-	
Net noncash loss on disposal of assets	7.3		2.0		3.4		1.4	
Loss on early extinguishment of debt	28.2		5.9		12.5		12.3	
Stock-based compensation expense	10.6		11.7		13.4		16.4	
Other	0.4		-		0.4		0.2	
Adjusted EBITDA ⁽¹⁾	\$ 306.7		\$ 322.6		\$ 363.7		\$ 409.6	
Weighted average common shares outstanding:								
Basic		78.7		83.0		88.8		92.8
Diluted		92.0		96.4		103.3		108.5

(1) (2) – Notes on page 40.

Reconciliation Notes for Slides 36-39

1. Adjusted EBITDA is a non-GAAP financial measure. The Company's leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP financial measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future HealthSouth may incur expenses similar to the adjustments set forth.
2. Per share amounts for each period presented are based on diluted weighted average shares outstanding unless the amounts are antidilutive, in which case the per share amount is calculated using the basic share count after subtracting the quarterly dividend on the convertible perpetual preferred stock. The difference in shares between the basic and diluted shares outstanding is primarily related to our convertible perpetual preferred stock.

Net Cash Provided by Operating Activities Reconciled to Adjusted EBITDA

(Millions)	Q3		9 Months		Full Year				
	2012	2011	2012	2011	2011	2010	2009	2008	2007
Net cash provided by operating activities	\$ 107.2	\$ 55.1	\$ 302.2	\$ 213.2	\$ 342.7	\$ 331.0	\$ 406.1	\$ 227.2	\$ 230.6
Provision for doubtful accounts	(7.0)	(5.1)	(19.8)	(14.9)	(21.0)	(16.4)	(30.7)	(23.0)	(28.5)
Professional fees—accounting, tax, and legal	4.1	4.0	13.2	16.2	21.0	17.2	8.8	44.4	51.6
Interest expense and amortization of debt discounts and fees	23.5	26.3	69.8	96.3	119.4	125.6	125.7	159.3	229.2
UBS Settlement proceeds, gross	-	-	-	-	-	-	(100.0)	-	-
Equity in net income of nonconsolidated affiliates	3.3	3.1	9.7	8.8	12.0	10.1	4.6	10.6	10.3
Net income attributable to noncontrolling interests in continuing operations	(12.8)	(11.4)	(38.6)	(34.5)	(47.0)	(40.9)	(33.3)	(29.8)	(31.1)
Amortization of debt discounts and fees	(0.9)	(0.9)	(2.7)	(3.3)	(4.2)	(6.3)	(6.6)	(6.5)	(7.8)
Distributions from nonconsolidated affiliates	(2.4)	(4.2)	(7.9)	(9.7)	(13.0)	(8.1)	(8.6)	(10.9)	(5.3)
Current portion of income tax (benefit) expense	(0.6)	(0.1)	3.7	(1.5)	0.6	2.9	(7.0)	(72.8)	(330.4)
Change in assets and liabilities	13.0	37.4	51.4	65.7	49.9	2.8	(2.1)	50.6	5.5
Net premium paid on bond issuance/redemption	-	8.9	-	22.8	22.8	-	-	-	-
Change in government, class action and related settlements liability	(2.6)	-	(2.6)	(6.5)	(8.5)	2.9	11.2	7.4	171.4
Cash used in (provided by) operating activities of discontinued operations	0.2	(2.2)	(1.5)	(9.4)	(9.1)	(13.2)	(5.7)	(32.5)	(3.3)
Other	0.2	(0.4)	0.4	0.1	0.6	2.0	1.3	(1.4)	14.5
Adjusted EBITDA	\$ 125.2	\$ 110.5	\$ 377.3	\$ 343.3	\$ 466.2	\$ 409.6	\$ 363.7	\$ 322.6	\$ 306.7